Atle Fund Management AB
STOCKHOLM, V7
$372m in 39 US stocks at the end of 30 June 2026. The top 10 are 48.0% of the money. It changed about 15.9% of the portfolio this quarter.
Value
$372m
Stocks
39
Top 10 share
48.0%
Turnover
15.9%
What changed this quarter
New
Bought for the first time this quarter.
- BiogenBIIB3.6% of the fund
- Oruka TherapeuticsORKA1.4% of the fund
- Jade BiosciencesJBIO0.5% of the fund
Added
Bought more of a stock they already held.
- MerckMRK6.5% of the fund+459%
- CVS HealthCVS4.1% of the fund+515%
- Thermo Fisher ScientificTMO3.8% of the fund+21%
- Ionis PharmaceuticalsIONS2.9% of the fund+392%
- StrykerSYK2.6% of the fund+13%
- BridgeBio PharmaBBIO2.5% of the fund+12%
- CencoraCOR2.4% of the fund+33%
- NewAmsterdam PharmaNAMS2.3% of the fund+163%
- Abivax SAABVX2.1% of the fund+84%
- IncyteINCY1.7% of the fund+12%
- iRhythm HoldingsIRTC1.7% of the fund+142%
- Boston ScientificBSX1.7% of the fund+262%
- Tango TherapeuticsTNGX1.7% of the fund+564%
- IDEAYA BiosciencesIDYA0.9% of the fund+203%
- Pyxis OncologyPYXS0.8% of the fund+391%
- Compass TherapeuticsCMPX0.6% of the fund+2407%
Cut
Sold some of their stake.
- Eli LillyLLY9.6% of the fund-25%
- Johnson & JohnsonJNJ5.8% of the fund-8%
- AbbVieABBV4.4% of the fund-41%
- Revolution MedicinesRVMD3.7% of the fund-88%
- Neurocrine BiosciencesNBIX3.3% of the fund-19%
- Mirum PharmaceuticalsMIRM3.2% of the fund-49%
- Alkermes plc.ALKS3.0% of the fund-12%
- Beone MedicinesONC2.7% of the fund-16%
- Intuitive SurgicalISRG2.6% of the fund-65%
- Vertex PharmaceuticalsVRTX2.6% of the fund-17%
- Edwards LifesciencesEW2.5% of the fund-3%
- Krystal BiotechKRYS2.4% of the fund-36%
- InsmedINSM1.7% of the fund-40%
- Gilead SciencesGILD1.6% of the fund-4%
- Cardinal HealthCAH1.5% of the fund-78%
- Spyre TherapeuticsSYRE1.4% of the fund-9%
- DexcomDXCM1.3% of the fund-88%
- Bicara TherapeuticsBCAX1.2% of the fund-88%
- CelcuityCELC0.9% of the fund-76%
- Disc MedicineIRON0.9% of the fund-59%
Sold out
Sold their entire stake.
- AmgenAMGN-100%
- UnitedHealth GroupUNH-100%
- Soleno Therapeutics-100%
Holdings
- Beone MedicinesONC
- Share
- 2.7%
- Value
- $10m
- Shares
- 35,180
-16%
- Abivax SAABVX
- Share
- 2.1%
- Value
- $8m
- Shares
- 58,170
+84%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Eli LillyLLY | 9.6% | $36m | 29,821 | -25% |
| MerckMRK | 6.5% | $24m | 189,357 | +459% |
| Johnson & JohnsonJNJ | 5.8% | $22m | 85,425 | -8% |
| AbbVieABBV | 4.4% | $16m | 64,325 | -41% |
| CVS HealthCVS | 4.1% | $15m | 146,102 | +515% |
| Thermo Fisher ScientificTMO | 3.8% | $14m | 27,859 | +21% |
| Revolution MedicinesRVMD | 3.7% | $14m | 73,077 | -88% |
| BiogenBIIB | 3.6% | $14m | 62,781 | New |
| Neurocrine BiosciencesNBIX | 3.3% | $12m | 72,898 | -19% |
| Mirum PharmaceuticalsMIRM | 3.2% | $12m | 100,807 | -49% |
| Alkermes plc.ALKS | 3.0% | $11m | 213,329 | -12% |
| Ionis PharmaceuticalsIONS | 2.9% | $11m | 137,131 | +392% |
| Beone MedicinesONC | 2.7% | $10m | 35,180 | -16% |
| Intuitive SurgicalISRG | 2.6% | $10m | 24,656 | -65% |
| StrykerSYK | 2.6% | $10m | 30,283 | +13% |
| Vertex PharmaceuticalsVRTX | 2.6% | $10m | 19,131 | -17% |
| Edwards LifesciencesEW | 2.5% | $9m | 103,230 | -3% |
| BridgeBio PharmaBBIO | 2.5% | $9m | 124,707 | +12% |
| Krystal BiotechKRYS | 2.4% | $9m | 24,019 | -36% |
| CencoraCOR | 2.4% | $9m | 31,126 | +33% |
| NewAmsterdam PharmaNAMS | 2.3% | $8m | 248,848 | +163% |
| Abivax SAABVX | 2.1% | $8m | 58,170 | +84% |
| IncyteINCY | 1.7% | $6m | 56,953 | +12% |
| iRhythm HoldingsIRTC | 1.7% | $6m | 54,102 | +142% |
| Boston ScientificBSX | 1.7% | $6m | 146,381 | +262% |
| InsmedINSM | 1.7% | $6m | 58,378 | -40% |
| Tango TherapeuticsTNGX | 1.7% | $6m | 198,557 | +564% |
| Gilead SciencesGILD | 1.6% | $6m | 46,142 | -4% |
| Cardinal HealthCAH | 1.5% | $6m | 23,630 | -78% |
| Oruka TherapeuticsORKA | 1.4% | $5m | 54,886 | New |
| Spyre TherapeuticsSYRE | 1.4% | $5m | 57,030 | -9% |
| DexcomDXCM | 1.3% | $5m | 71,846 | -88% |
| Bicara TherapeuticsBCAX | 1.2% | $4m | 145,657 | -88% |
| IDEAYA BiosciencesIDYA | 0.9% | $4m | 94,478 | +203% |
| CelcuityCELC | 0.9% | $3m | 33,313 | -76% |
| Disc MedicineIRON | 0.9% | $3m | 43,682 | -59% |
| Pyxis OncologyPYXS | 0.8% | $3m | 966,459 | +391% |
| Compass TherapeuticsCMPX | 0.6% | $2m | 1,048,593 | +2407% |
| Jade BiosciencesJBIO | 0.5% | $2m | 88,556 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 59.1% since 30 June 2025.
Where the money is
Health care95.2%
Other4.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.